Modulation of Oral Microflora during <em>Helicobacter Pylori </em>Eradication

J Coll Physicians Surg Pak. 2022 Mar;32(3):308-312. doi: 10.29271/jcpsp.2022.03.308.

Abstract

Objective: To analyse the saliva microbial abundance and composition by 16s rRNA sequence during Helicobacter pylori (H.pylori) eradication.

Study design: Descriptive study.

Place and duration of study: Hebei University of Chinese Medicine, Hebei Provincial Hospital of Traditional Chinese Medicine, from March 2019 to January 2020.

Methodology: The saliva microbial were analysed before and after the bismuth-containing quadruple therapy. A total of ten saliva samples (three groups) were enrolled in the study. The authors used the linear discriminant analysis effect size (LEfSe) method and Welch's t-test for comparative analysis to identify which taxa could be significantly affected in three groups.

Results: H.pylori 16S rRNA gene sequence was not detected in the ten saliva samples. The abundance of Prevotella_sp._oral_clone_P4PB_83_P2 from healthy adults was higher than H.pylori-positive patients. Moreover, after the bismuth-containing quadruple therapy, the diversity and richness of saliva bacteria reduced. Lautropia, Burkholderiales, uncultured bacterium, Burkholderiaceae, and Actinomyces were enriched in H.pylori-positive patient samples after the bismuth-containing quadruple therapy.

Conclusion: The diversity and richness of salivary microbiome were reduced in H.pylori-positive patient, and bismuth-containing quadruple therapy affected oral microbiota. Key Words: Helicobacter pylori, Saliva, Microbiota, RNA, Bismuth.

MeSH terms

  • Adult
  • Amoxicillin
  • Anti-Bacterial Agents / therapeutic use
  • Drug Therapy, Combination
  • Helicobacter Infections* / drug therapy
  • Helicobacter pylori* / genetics
  • Humans
  • Microbiota*
  • Proton Pump Inhibitors / therapeutic use
  • RNA, Ribosomal, 16S / genetics

Substances

  • Anti-Bacterial Agents
  • Proton Pump Inhibitors
  • RNA, Ribosomal, 16S
  • Amoxicillin